Scientists studied 188 people related to someone with ALS caused by a C9ORF72 mutation to identify markers of disease risk in ...

Alzheimer's disease is one of the world's biggest health problems. Yet, despite the fact millions of people globally are ...

Complex problems often require creative solutions, and the increasing global burden of Alzheimer’s disease certainly ...

In 1992, Judith Frydman, PhD, discovered a molecular complex with an essential purpose in all of our cells: folding proteins correctly.

Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its ...

A new study represents a significant step forward in scientists' understanding of Alzheimer's disease. A team of investigators has examined the role of two proteins found in the brain and suggest the ...

A new study from the University of Liverpool represents a significant step forward in scientists' understanding of Alzheimer's disease.

This manuscript provides fundamental studies to help us better understand the effects of mutations in the presenilin-1 (PSEN1) gene on proteolytic processing of the amyloid precursor protein (APP).

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...

"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment ...